Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangshen prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by the Taizhou Hospital of Traditional Chinese Medicine for the treatment of diabetic kidney disease (DKD) and type 2 diabetes mellitus. The prescription is designed around the concept of "co-management of sugar, kidney, and syndrome," which seeks to integrate Western medical standards for DKD management with TCM macro syndrome differentiation. It is intended for use in non-dialysis patients to improve both clinical symptoms and biochemical markers of disease progression. The formula is currently undergoing clinical evaluation to further elucidate its therapeutic mechanisms and support its broader clinical application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangshen prescription.